Kite-197
Relapsed/Refractory Large B-cell Lymphoma
Kite, A Gilead Companygene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
107 Active assets in the Relapsed/Refractory Large B-cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Selinexor Chengdu Zenitar Biomedical Technology Co., Ltd | Phase 3 | BB |
DEXAMETHASONE City of Hope Medical Center | Phase 2/3 | BB |
Ifosfamide University of California, Davis | Phase 3 | BB |
Cyclophosphamide Nathan Denlinger | Phase 3 | BB |
Axicabtagene Ciloleucel Zhujiang Hospital | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Kite-197 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →